Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH - Free Report) had its price target upped by Oppenheimer from $48.00 to $52.00 in a report issued on Monday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Several other analysts have also recently commented on the company. Raymond James lifted their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a report on Friday. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an "outperform" rating and a $58.00 price objective for the company. Wedbush cut their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Finally, Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Dianthus Therapeutics has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Stock Down 4.5 %

Shares of DNTH traded down $1.31 on Monday, hitting $27.75. 225,157 shares of the stock traded hands, compared to its average volume of 193,518. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The stock's 50 day moving average is $27.75 and its two-hundred day moving average is $26.55. The firm has a market capitalization of $815.02 million, a P/E ratio of -11.58 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 22.37% and a negative net margin of 1,250.32%. Research analysts forecast that Dianthus Therapeutics will post -2.28 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. Quest Partners LLC raised its holdings in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares during the period. SG Americas Securities LLC bought a new position in Dianthus Therapeutics in the second quarter worth about $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the second quarter valued at approximately $236,000. WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $265,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $334,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.